MM120 · program

Lysergide D-tartrate (MM120 / LSD) for Major depressive disorder

Phase 3RecruitingDefinium Therapeutics, Inc. (DFTX)

Indications for MM120: Generalized anxiety disorder · Phase 3 Major depressive disorder · Phase 3 Post-traumatic stress disorder · Phase 3 Attention-deficit/hyperactivity disorder · Discontinued

MM120 (DT120) for major depressive disorder — second indication after the lead GAD program. Phase 3 'Emerge' study (NCT06941844) evaluates a single dose for MDD. Builds on MM120's Phase 2b anxiety data and the GAD Phase 3 program (Voyage/Panorama).

Data current as of

Development timeline

Phase 3Aug 2023 – Jun 2026
  1. FinancingDefinium Therapeutics closes upsized $805M public equity offering (~$758M net) funding DT120 program↗
  2. metPhase 3 Emerge topline: single-dose DT120 ODT meets primary in MDD (MADRS −8.1 pts vs placebo at Week 6, p<0.0001)↗
  3. Trial startedFirst patient dosed in Ascend, the second Phase 3 pivotal study of DT120 ODT in MDD↗
  4. Enrollment completeEmerge (Phase 3, DT120 ODT in MDD) completes enrollment with 149 participants↗
  5. Corporate rebrand / name changeMind Medicine (MindMed) rebrands as Definium Therapeutics↗
  6. Phase 3 MDD program (Emerge, NCT06941844) initiated. Date approximate.
  7. Licensing dealCatalent grants MindMed exclusive license to Zydis ODT technology for MM-120 (lysergide)↗

Readouts

  • 2026-06-22ReportedTopline datamet

    Phase 3 Emerge topline: single-dose DT120 ODT meets primary in MDD (MADRS −8.1 pts vs placebo at Week 6, p<0.0001) ↗

Clinical trials in Major depressive disorder

NCT07592689Phase 3Recruitingn=165

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

Started May 2026· Primary completion Sept 2027· 📍 27 sites across 1 country (United States)

NCT06941844EmergePhase 3Recruiting

Phase 3 Study of MM120 (Lysergide) in Major Depressive Disorder (Emerge)

· 📍 25 sites across 1 country (United States)

Formulations

FormulationRouteRegimenPharmacokinetics
DT120 orally disintegrating tablet (ODT)Orally disintegrating tablet (ODT) using Catalent Zydis fast-dissolve technology
Proprietary orally disintegrating tablet of lysergide (LSD) D-tartrate; single administration; designed for faster absorption and onset
OralSingle dose—

Mechanism of action (compound-wide)

LSD acts across serotonin receptor subtypes; the company describes MM120 as a 5-HT2A partial agonist (IUPHAR classifies LSD as a full 5-HT2A agonist). Antidepressant effects attributed primarily to 5-HT2A agonism.

TargetActionAffinity
5-HT2AprimaryHTR2APartial agonistpKi 9.4ⓘ
5-HT1AHTR1AAgonistpKi 9ⓘ
5-HT2CHTR2CAgonistpKi 8.2ⓘ

← Full MM120 compound page (identity, identifiers, all indications)

Sources

  1. Definium Therapeutics (DFTX) maps DT120 ODT Phase 3 readouts and PTSD expansion (8-K) — Definium Therapeutics, Inc.
  2. Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder — Definium Therapeutics, Inc.
  3. Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder — Definium Therapeutics
  4. Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares — Definium Therapeutics, Inc.
  5. DT120 ODT — LSD Therapy for Depression and Anxiety — Definium Therapeutics
  6. clinicaltrials.gov — clinicaltrials.gov
  7. Lysergide (LSD), Ligand 17 — IUPHAR/BPS
  8. MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis Fast-Dissolve Technology for Use with MM-120 — MindMed / Definium Therapeutics
  9. MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026 — Definium Therapeutics
  10. MM120 Emerge Phase 3 MDD (NCT06941844) — ClinicalTrials.gov